Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BNTC
SellSinkerBenitec Biopharma Inc. · Healthcare · United States · $428M · Avg Vol: $2M/d
COMPANY DESCRIPTION
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) platform. This technology combines gene therapy with RNA interference to provide sustained, single-administration silencing of disease-causing genes, with a primary focus on treating Oculopharyngeal Muscular Dystrophy (OPMD). Benitec operates as a pioneer in the gene-silencing space, targeting rare genetic diseases with high unmet clinical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 73.0K | 75.0K | 0 | 0 | 2.7% | — | — | 18.2M | 294.8% |
| EPS | -0.53 | -0.68 | -0.36 | -1.05 | — | -0.93 | -0.99 | -1.11 | — |
| Shares | 34.4M | 34.4M | 34.4M | 26.3M | -23.6% | 34.4M | — | — | — |
| Debt | 0.8M | 0.6M | 0.3M | 0.8M | 1.5% | 0.9M | — | — | — |
| Equity | 2.9M | 0.2M | 47.2M | 97.3M | 223.2% | — | — | — | — |
| Op CF | -15.9M | -18.0M | -19.4M | -23.6M | — | -19.8M | — | — | — |
| Inv CF | -13.0K | -1.0K | -0.2M | -18.0K | — | — | — | — | — |
| Fin CF | 0 | 16.0M | 68.0M | 70.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BNTC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc.(you) | $428M | 23 | Sell |
| ARCT | Arcturus Therapeutics Holdings Inc. | $432M | 25 | Sell |
| PRLD | Prelude Therapeutics Incorporated | $437M | 25 | Sell |
| RZLT | Rezolute, Inc. | $445M | 21 | Sell |
| PRTC.L | PureTech Health plc | $415M | 27 | Sell |
| XFOR | X4 Pharmaceuticals, Inc. | $401M | 26 | Sell |
| RLMD | Relmada Therapeutics, Inc. | $462M | 20 | Sell |
| SABS | SAB Biotherapeutics, Inc. | $345M | 23 | Sell |
| DNA | Ginkgo Bioworks Holdings, Inc. | $469M | 20 | Sell |
| CCCC | C4 Therapeutics, Inc. | $474M | 27 | Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%